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ABSTRACT 18 
Short telomeres are associated with increased risk of cardiovascular disease. Here we studied 19 
cardiomyocyte telomere length at key ages during the ontogeny of cardiac hypertrophy and 20 
failure in the hypertrophic heart rat (HHR), and compared these with the normal heart rat 21 
(NHR) control strain. Key ages corresponded with the pathophysiological sequence 22 
beginning with fewer cardiomyocytes (2-days), leading to left ventricular hypertrophy (LVH) 23 
(13-weeks) and subsequently progression to heart failure (38-weeks). We measured telomere 24 
length, tissue activity of telomerase, mRNA levels of telomerase reverse transcriptase (Tert) 25 
and telomerase RNA component (Terc), and expression of the telomeric regulator microRNA 26 
miR-34a. Cardiac telomere length was longer in the HHR compared to the control strain at 2-27 
days and 38-weeks, but shorter at 13-weeks. Neonatal HHR had higher cardiac telomerase 28 
activity and expression of Tert and miR-34a. Telomerase activity was not different at 13- or 29 
38-weeks. Tert mRNA and Terc RNA were over-expressed at 38-weeks, while miR-34a was 30 
over-expressed at 13-weeks but down-regulated at 38-weeks. Circulating leukocytes were 31 
strongly correlated with cardiac telomere length in the HHR only. The longer neonatal 32 
telomeres in HHR are likely to reflect fewer foetal and early postnatal cardiomyocyte cell 33 
divisions and explain the reduced total cardiomyocyte complement that predisposes to later 34 
hypertrophy and failure. Although shorter telomeres were a feature of cardiac hypertrophy at 35 
13-weeks, they were not present at the progression to heart failure at 38-weeks. 36 
 37 
Keywords: cardiac hypertrophy, left ventricular hypertrophy, development, telomeres, 38 
telomerase, miRNA, Terc, Tert.39 
Marques, Booth et al. R2 
3 
 
INTRODUCTION 40 
Telomeres, the specialized DNA-protein complexes located at the ends of eukaryotic 41 
chromosomes, are essential for chromosomal stability and cell viability. Telomere length and 42 
its age-dependent shortening is regarded as a marker of age-associated diseases in general 43 
and cardiovascular disease in particular (36). This is strongly supported by investigations 44 
showing that patients with atherosclerosis, coronary artery disease, chronic heart failure and 45 
stroke have shorter leukocyte telomere length (LTL) (4, 12, 15, 41, 44). There are, however, 46 
some paradoxical findings that are not understood in regards to telomere length and left 47 
ventricular (LV) hypertrophy – one of the key indicators of target-organ damage in 48 
cardiovascular disease (23). For example, population-based studies have shown that LV mass 49 
and thickness were associated with longer, rather than shorter, telomeres (18, 42). This is 50 
difficult to explain since LV mass represents the time-averaged exposure to several 51 
cardiovascular risk factors which also decrease telomere length,, such as age, inflammation, 52 
oxidative stress, blood pressure (BP) and obesity, combined with genetic factors (6, 7, 22).  53 
Less well studied is the importance of cardiac telomere dynamics to the developmental 54 
changes in cardiac mass leading to failure. Indeed, shorter telomeres at an early age can lead 55 
to impairment in cell division, enhanced cardiomyocyte death and hypertrophy, all of which 56 
are concomitant with cardiac dysfunction and failure (21). Animal models have been be used 57 
to assess changes in telomeres (21), but in the case of LV hypertrophy this maybe hindered 58 
by the associated increased BP (11, 29), and, hence, mask the genetic origin of this disease. 59 
All of the above highlight the need to elucidate specific pathways that affect telomere length 60 
throughout the lifespan in the absence of increased BP. Crucial to our understanding of the 61 
molecular mechanisms that underlie the development of LV hypertrophy and heart failure, 62 
and to the design of preventive and therapeutic regimens are animal models that are bred to 63 
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genetically develop LV hypertrophy leading to heart failure. One such model is the 64 
hypertrophic heart rat (HHR), which develops LV hypertrophy independent of hypertension 65 
(14).  66 
Given the established link between telomere dysfunction and cardiomyocyte 67 
proliferative defects (21), we postulated that cardiac telomere homeostasis will be perturbed 68 
in the HHR. To test this hypothesis, we first measured telomere length in the heart of the 69 
HHR at key ages corresponding to the pathophysiological sequence of fewer cardiomyocytes 70 
(2-days), cardiac hypertrophy (13-weeks) and subsequently progression to heart failure (38-71 
weeks).  In the search for the molecular basis of perturbed telomere homeostasis in the HHR 72 
heart, we first measured changes in the telomere lengthening enzyme telomerase and 73 
quantified its two main subunits – telomerase reverse transcriptase (Tert) and telomerase 74 
RNA component (Terc). We also investigated whether changes in telomere length are due to 75 
changes in the newly discovered telomeric regulator microRNA (miRNA) miR-34a (3, 33). 76 
Our findings are the first to describe telomere dynamics in cardiac hypertrophy independent 77 
of BP. They point to a key involvement of miR-34a and Tert as direct drivers of telomeres 78 
and, hence, the dynamic regulation of cardiomyocyte growth and function. 79 
 80 
MATERIALS AND METHODS 81 
Animal Models. The HHR is a polygenic model of LV hypertrophy developed by cross-82 
breeding the spontaneously hypertensive rat, a model of hypertension and LV hypertrophy, 83 
and the Fischer 334 rat, which has normal blood pressure and cardiac size. The progeny were 84 
selectively interbred over 13 generations to create the HHR, which presents with pathological 85 
LV hypertrophy in the absence of a pressure load at maturity. The sister strain used as a 86 
control is the normal heart rat (NHR), which has normal heart size and blood pressure (14). 87 
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The HHR is born with a smaller heart containing fewer cardiomyocytes (31). By 12 weeks of 88 
age, however, the HHR presents with established LV hypertrophy, which leads to premature 89 
death due to heart failure as early as 48 weeks of age (14, 31). 90 
Samples and Tissue Collection. 2-day old HHR (n =7) and NHR (n=9) were euthanized by 91 
decapitation. 13-week old (n=9 HHR and n=11 NHR) and 38-week old (n=9 HHR and n=7 92 
NHR) were euthanized with an overdose of pentobarbitone (Lethobarb) (Table 1). Hearts 93 
were immediately removed, and LV dissected from the atria. Cardiac weight index (CWI, 94 
mg/g) was calculated from the total heart weight (mg) relative to total body weight (g) of the 95 
animal. Circulating leukocytes were collected in heparin tubes from 13-week old rats only. 96 
Tissues were first preserved in liquid nitrogen and later transferred to a –80oC freezer. 97 
Cardiomyocytes were isolated from snap frozen tissue. The protocol was adapted from a 98 
publication (26) and personal communication to Prof Cris dos Remedios (University of 99 
Sydney). Briefly, the tissue was sectioned into 300 μm sections and stored at -20°C for 4 100 
hours. We then added 1 mL of digestion buffer (PBS, 1mg/mL collagenase B, 1mg/ml 101 
collagenase D, and 30mM BDM, filtered using a 0.22 μm filter) for every 300 μm cardiac 102 
section and digested immediately for 20 min on an incubated rocking plate (37 °C, 99 RPM). 103 
The tubes containing the tissue where placed one ice and manually digested by pipetting the 104 
solution up and down repeatedly (~20 times with a 10ml sterile pipette). This was repeated 3 105 
times. The solution was then passed through a 100 μm mesh filter and increasing volumes of 106 
RCGM media (Lonza) were added (0.1, 0.1, 0.3 and 05 volumes), with 10 minutes rest 107 
intervals on ice. The cell pellet was collected by centrifugation at 200 RPM for 4 minutes at 4 108 
°C, and this was used for extractions described below. The study was approved by the 109 
Animal Ethics Committees of the University of Melbourne and Deakin University, and 110 
ratified at Federation University Australia.  111 
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DNA and RNA Extraction. DNA from leukocytes, cardiomyocytes and LV tissue was 112 
extracted using the PureLink® Genomic Extraction kit (Life Technologies). RNA was 113 
extracted using the miRNeasy kit (Qiagen). Both RNA and DNA were quantified by 114 
spectrophotometry using a NanoDrop® ND-100 spectrophotometer (Thermo Scientific).  115 
Telomere Length Measurement. The telomere-repeat copy number (T) to single-copy gene (a 116 
gene with only one locatable region on a DNA molecule) copy number (S) ratio (T/S ratio) 117 
was determined by real-time quantitative PCR (qPCR) using SensiMix SYBR No-Rox 118 
(Bioline) in a Viia7 instrument (Life Technologies), as previously described (5). We then 119 
used the formula (3,274 + 2,413 * (T/S)) to convert T/S ratio to base pairs (28). Telomere 120 
length was given as T/S ratio and base pairs.  121 
Telomerase activity. Telomerase activity was measured using the TRAPeze® Kit RT 122 
Telomerase Detection Kit (Merck Millipore) and Platinum® Taq DNA Polymerase (Life 123 
Technologies) according to the supplier. Briefly, protein was extracted using the CHAPS 124 
Lysis Buffer (Merck Millipore), and one µg of protein was added to each reaction. Samples 125 
were measured in duplicate, and telomerase activity was quantified relative to a standard 126 
curve by qPCR in a Viia7 instrument (Life Technologies). The activity of the enzyme 127 
telomerase was given as a number of copies determined based on the standard curve supplied 128 
by Merck Millipore. 129 
MicroRNA and gene expression. The levels of Tert and Terc, both components of telomerase, 130 
the enzyme responsible for the elongation of telomeres, and protein phosphatase 1 regulatory 131 
subunit 10 (Ppp1r10, also known as Pnuts) mRNA, and miR-34a were measured using 132 
qPCR. For mRNA levels, the first-strand complementary synthesis reaction was performed 133 
using the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Primers were 134 
designed to flank an exon-exon junction using Primer3 (35) and NCBI tool Primer Blast. 135 
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Amplification reactions used the SensiFastTM SYBR Low-ROX Kit qPCR reagent (Bioline). 136 
The specificity of qPCRs was ensured by melting curve analysis and DNA gel 137 
electrophoresis (data not shown). For miR-34a expression, RNA was transformed to cDNA 138 
using the TaqMan® MicroRNA Reverse Transcription Kit for miRNA cDNA (Life 139 
Technologies). Amplification reactions used TaqMan assays and the TaqMan® Fast 140 
Advanced Master Mix (Life Technologies). For both mRNA and miRNA expression, all 141 
samples were run in duplicates in a Viia7 qPCR instrument (Life Technologies). 142 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as reference transcript for 143 
mRNA levels, and the miRNAs RNU6, 4.5S and Sno87 for miRNA expression. Primers, 144 
probe assays and conditions are listed in Table 2. Significance was assessed using 2-ΔΔCT for 145 
both mRNA and miRNA expression calculations (37).   146 
Statistical Analyses. GraphPad Prism (version 6) and SPSS (version 21) packages were used 147 
for graphing and statistical analyses. Data sets were tested for normal distribution using the 148 
D'Agostino & Pearson normality test, and equal variances were analysed using the F test. An 149 
independent sample t-test, Welch’s test, or Mann-Whitney test were used to compare the data 150 
between the groups. Pearson’s or Spearman’s correlations were used to correlate telomere 151 
length, miR-34a and telomeric gene expression, and CWI data. Analyses of variance 152 
(ANOVA) using Tukey's multiple comparisons test was used to compare between ages 153 
within the same strain. Step-wise regression analyses were used to determine potential 154 
predictors of cardiac size and telomere length, including age and sex as independent variables 155 
(F-entry probability: 0.05, removal: 0.1). Significance was set at P<0.05. 156 
 157 
RESULTS 158 
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Cardiac Size. Table 1 provides the characteristics of the samples used in this study. Neonatal 159 
2-day old HHR had significantly smaller hearts (P=0.0008), while 13- and 38-week old 160 
animals had significantly larger hearts (all P<0.05) relative to age-matched NHR (Table 1, 161 
Figure 1A).  162 
Left Ventricular Telomere Length. There was a positive correlation between telomere length 163 
of isolated cardiomyocytes and whole LV at all ages (r=0.295, P=0.017). LV telomere length 164 
was significantly longer in 2-day old HHR (NHR T/S ratio 3.23±0.07 vs HHR 3.51±0.1, 165 
NHR 11,068 bp vs HHR 11,743 bp, P=0.023), but shorter in 13-week old HHR (NHR 166 
3.38±0.04 vs HHR 3.26±0.03, NHR 11,430 bp vs HHR 11,140 bp, P=0.024) compared to 167 
age-matched NHR (Figure 1B). In 38-week old HHR, LV telomere length was significantly 168 
longer than the NHR (NHR 2.88±0.2 vs HHR 3.34±0.04, NHR 10,223 bp vs HHR 11,333 bp, 169 
P=0.009, Figure 1B). When we compared LV telomere length within strains, 2-day old HHR 170 
had significantly longer telomeres than 13-week old HHR (P=0.01, Figure 1B). Thirty-eight-171 
week old NHR had significantly shorter telomeres compared to 13-week old (P=0.004, 172 
Figure 1B).  173 
Leukocyte Telomere Length. To investigate whether telomere length of circulating leukocytes 174 
is a marker of LV telomere length, we measured telomere length in circulating leukocytes 175 
and matching LV tissue from 13-weeks old NHR and HHR. As with LV telomere length, 176 
LTL was significantly shorter in 13-weeks old HHR compared to age-matched NHR (NHR 177 
3.65±0.07 vs HHR3.47±0.06, NHR 12,081 bp vs NHR 11,647 bp, P=0.048, Figure 1C). 178 
Moreover, there was a positive correlation between cardiac and leukocyte telomere length 179 
(r=0.448, P=0.031, Figure 1D). This correlation was driven by the HHR (r=0.81, P=0.026), 180 
while in the NHR we did not find a significant correlation (r=0.18, P=0.605). 181 
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Telomerase Activity. In accordance to telomere length, neonatal HHR had significantly higher 182 
telomerase activity (NHR 13768±1254 vs HHR 51040±4618, P<0.0001, Figure 2A), 183 
however at 13- (NHR 1416±350.6 vs HHR 786.8±181.1, P=0.146) and 38-week old (NHR 184 
808.1±307.2 vs HHR 809.3±213.4, P=0.997) we did not discover significant difference in 185 
telomerase activity between strains (Figure 2A). Neonatal NHR and HHR had significantly 186 
higher telomerase activity than all other ages (all P<0.01, Figure 2A). Moreover, telomerase 187 
activity was correlated to telomere length (r=0.27, P=0.035, Figure 2B), especially in the 188 
control strain (r=0.51, P=0.005, Figure 2C).  189 
Genes Involved in Telomere Maintenance. Tert mRNA was up-regulated in 2-days (+1.4, 190 
P=0.021) and 38-weeks old HHR (+19.0, P<0.001) (Figure 2D) compared to age-matched 191 
NHR, while we did not discover significant difference at 13-weeks (+1.3, P=0.07). In the 192 
NHR, Tert mRNA was the lowest at 38-weeks of age, at the same that the shorter telomeres 193 
were observed (Figure 2D). In the HHR, Tert mRNA was highest in 2-days and 38-weeks 194 
old. In accordance to telomere length, Tert mRNA was the lowest at 13-weeks of age (Figure 195 
2D).  196 
Terc RNA levels did not significantly differ between the HHR and NHR in 2-day (–1.1, 197 
P=0.264) and 13-week old animals (–2.1, P=0.098) (Figure 2E). 38-week old HHR had 198 
significantly higher Terc RNA (+1.94, P=0.018, Figure 2E). In both NHR and HHR, Terc 199 
RNA was significantly higher at 38-weeks of age compared to all other age groups (Figure 200 
2E). 201 
miR-34a and Ppp1r10 Expression. The miRNA miR-34a was significantly over-expressed in 202 
HHR compared to the NHR at 2-days (+1.9, P=0.004) and 13-weeks (+1.8, P<0.0001), but 203 
down-regulated at 38-weeks (–6.9, P=0.019) of age (Figure 3A). In regards to miRNA levels 204 
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within strains, miR-34a had the highest expression at 38-weeks of age compared to other ages 205 
in the both the NHR (Figure 3A) and HHR strains (Figure 3A) (all P<0.01).  206 
 Ppp1r10 was previously described as a target of miR-34a in the mouse heart (3). It 207 
also plays a role in the regulation of anti-apoptotic effects in cardiomyocytes (3). Since miR-208 
34a is over-expressed in the HHR, we measured Ppp1r10 levels. Ppp1r10 mRNA was non-209 
significantly down-regulated in the HHR compared to the NHR at 2-days (–1.2, borderline 210 
P=0.062) and 13-weeks (–1.35, P=0.14, Figure 3B), but over-expressed at 38-weeks (+28.1, 211 
P<0.001) of age (Figure 3B). In regards to Ppp1r10 expression within strains, mRNA levels 212 
in the HHR were significantly lower at 13-weeks of age (P<0.0001, Figure 3B). In the NHR, 213 
Ppp1r10 mRNA levels were significantly higher at 2-days (P<0.0001) and lower at 38-weeks 214 
of age (P=0.012, Figure 3B). Ppp1r10 mRNA was borderline negatively correlated with 215 
miR-34a levels in all ages besides 38-weeks (2-day r=–0.38, P=0.067 and 13-week old r=–216 
0.35, P=0.067).  217 
Regression Analyses. In a step-wise regression analysis, Tert mRNA and miR-34a levels 218 
were the only statistically significant predictors of heart telomere length in both strains at all 219 
ages (Table 3). According to the standardised β coefficients, miR-34a effect was stronger 220 
than Tert levels. In a similar analysis of the development of hypertrophy (2-days and 13-221 
weeks old), Tert was the only determinant of cardiac telomere length (β=0.02, SE=0.008, 222 
P=0.01). In post-neonatal development, miR-34a was the only molecular variable negatively 223 
associated with telomere length (β=–0.02, SE=0.003, 95% C.I. –0.031 to –0.017, P=0.001), 224 
suggesting its effects are independent of telomerase activity at this age. Similar results were 225 
found in 38-week old HHR (β=–0.02, SE=0.005, 95% C.I. –0.031 to –0.011, P=0.001). 226 
 227 
DISCUSSION 228 
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Dissecting the effect of telomere length on polygenic LVH and heart failure has been 229 
hindered by the difficulty of obtaining human cardiac tissue and by the lack of animal models 230 
for the disease that are not affected by pressure overload. Here we set out to investigate the 231 
changes in telomere length during the development of polygenic LVH and progression to 232 
heart failure. The hypertrophic model is born with longer telomeres, higher telomerase 233 
activity and smaller hearts compared to the normal strain. This is followed by accelerated 234 
shortening of telomeres paralleled to an increase in LV mass. Changes in telomere length 235 
were linked to dysregulation of the telomeric regulators miR-34a and Tert mRNA in the 236 
hypertrophic strain. Other molecular changes associated with telomere length at some ages 237 
included fluctuations in Ppp1r10 mRNA, Terc RNA and telomerase activity. These findings 238 
indicate an increased impairment in cell division (21) during a crucial age for heart 239 
development (27, 32) which then restricts the response of the remaining cardiomyocytes to 240 
hypertrophy and predisposes the heart to failure (16). 241 
The concept of being born smaller and having longer telomeres, as observed in the 242 
HHR, is consistent with results found in young men born small due to intra-uterine growth 243 
restriction (19). The longer telomeres in 2-day old HHR could, at least in part, be genetically 244 
determined and be due to fewer cell divisions in the heart during embryogenesis. This would 245 
also explain the fewer cardiomyocytes previously found in this strain (31). Furthermore, 246 
recent studies in mice have shown that cardiomyocytes proliferate until post-natal day 7 (32), 247 
which is followed by another proliferative burst in the third week of life (27). In this regard, it 248 
is possible that cardiomyocytes in the HHR may be forced to divide more to compensate for 249 
their lower cell number, which would contribute to the accelerated telomere attrition between 250 
2-days and 13-weeks of age. Furthermore, cardiomyocytes produced from cells with short 251 
telomeres inherit this defect and quickly acquire the senescent phenotype (16). This limits the 252 
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adaptive response of these cells to hypertrophy (16, 34), highlighting the possible causal 253 
involvement of short telomeres in cardiomyocyte hypertrophy.  254 
In the current study we also found significantly higher telomerase activity in neonatal 255 
HHR which could contribute to the longer telomeres in these animals. In the HHR, 256 
telomerase activity decreased by 60 times between 2-days and 38-weeks of age, while in the 257 
NHR this was phenomenon was less accentuated (17 times less telomerase activity at 38-258 
weeks). This acute decrease in telomerase activity is likely to contribute to the reduced 259 
telomere length in the HHR as well as possibly reduce cell viability independently of 260 
telomere length as previously found in endothelial cells (13, 39, 43).  261 
Another key finding of this study was the over-expression of miR-34a since neonatal 262 
age in the HHR. During normal development, over-expression of miR-34a was only 263 
previously reported in the ageing heart, a phenomenon which leads to cell death.14 This 264 
suggests that the up-regulation of this miRNA early in life could be involved in the reduced 265 
complement of cardiomyocytes of this strain (31), thereby inducing compensatory 266 
hypertrophy in the remaining cardiomyocytes (16, 34).  After two days, postnatally 267 
accelerated telomere shortening is driven by miR-34a and this is likely to contribute to the 268 
development of LV hypertrophy. Indeed, therapies targeting miR-34a or miR-34 family, such 269 
as the ones administered by Bernardo and colleagues (1, 2), were shown to have beneficial 270 
effects in the diseased heart. Furthermore, we found that Ppp1r10 mRNA, a target of miR-271 
34a, was down-regulated in the HHR and this gene is known to have an important role in 272 
telomere maintenance by directly interacting with non-redundant shelterin protein, telomeric 273 
repeat binding factor 2 (Trf2) (17, 30). Indeed in primary rat cardiomyocytes, defective 274 
expression of Trf2 causes accelerated telomere attrition and increased apoptosis (30). 275 
Furthermore, Trf2 protects against apoptosis even in non-dividing cells (20), highlighting its 276 
importance in the mostly non-mitotic heart.  277 
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 Consistent with the documented positive correlation between LV mass and longer LTL 278 
in humans (18, 42), 38-week old HHR had significantly longer telomeres than the age-279 
matched controls. Importantly, however, our data indicate that telomere length in the HHR 280 
does not show significant increase with ageing (2 days old 11,743 bp vs 38-weeks old 11,333 281 
bp). Instead, telomeres were longer at birth, and then become shorter early in development, 282 
with no significant changes observed thereafter. Indeed, cardiomyocyte division in adulthood 283 
happens at a slower pace, accounting for only a fraction of the telomere attrition observed 284 
throughout the lifespan (32). In the NHR, however, telomeres got significantly shorter later in 285 
life, between 13- and 38-weeks of age. These findings suggest that the relative importance of 286 
the various mechanisms involved in telomere maintenance differ between normal and 287 
hypertrophic hearts.  288 
The longer telomere length in the presence of LV hypertrophy may seem paradoxical, 289 
but the adaptive response of the heart to stress is a ubiquitous theme in the literature. For 290 
instance, cardiomyocyte division and telomerase activity in dogs were increased with the 291 
onset and further again with the progression of ventricular dysfunction (24). Similar results 292 
have been found in human hearts after myocardial infarction (40). Furthermore, in a mouse 293 
model of Akt-induced LV hypertrophy, increased expression of angiogenic growth factors are 294 
found in the adaptive phase of hypertrophy, but a reduction in the transition to heart failure 295 
(38). Taken together, these findings demonstrate that acute stress on the heart induces 296 
compensatory mechanisms that become attenuated then exhausted if the disease progresses. 297 
In this regard, it would be interesting to determine telomere length in the HHR at the time of 298 
death due to heart failure, which begins to occur around 48 weeks of age (31), but 299 
unfortunately samples were not available. Based on this explanation, we would expect a 300 
sharp decrease in telomere length in the failing heart, which has been well documented 301 
previously (30, 41, 45). 302 
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Although the use of qPCR to measure relative telomere length is widely used in the 303 
literature (6, 7, 10), this needs to be acknowledged as a limitation. Previous studies, however, 304 
have shown that this method is reliable and the results are highly comparable to other 305 
techniques, such as mean terminal restriction fragment (TRF) length (5), Southern blots and 306 
single telomere length analysis (STELA) (25). Moreover, we have previously shown that 307 
telomere length varies according to the method of DNA extraction (9). In the present study, 308 
all samples were collected, processed and extracted using the same method, and samples 309 
were run in the same qPCR plate to minimise variation. Therefore, we believe the results 310 
presented here are highly robust.  311 
In this study we showed a correlation between LTL and telomere length in both LV 312 
tissue and isolated cardiomyocytes. Consistent with the established phenomenon of telomere 313 
synchrony (8), our findings support the use of LTL as a marker of LV telomere length in 314 
hypertrophic hearts (r=0.81, P=0.026), albeit we did not find a correlation in the control 315 
strain. Furthermore, the accelerated shortening of telomeres early in the life of the 316 
hypertrophic model suggests that telomere attrition plays an important role in the 317 
development of LV hypertrophy. Our data also support the hypothesis that Tert mRNA and 318 
miR-34a are the main determinants of telomere length. We found dysregulation of miR-34a 319 
from an early age, which may play a role in both telomere attrition and cell death, further 320 
predisposing to the development of LV hypertrophy.  321 
Short telomeres in leukocytes are associated with increased heart disease. LVH is one 322 
of the main risk factors for heart disease, yet the effect of telomere length on this condition is 323 
still poorly understood, mainly due to the influence of blood pressure on cardiac mass. This 324 
study demonstrates that telomeres in cardiomyocytes have an important role in the 325 
development of LVH in a normotensive model. There is accelerated shortening of telomeres 326 
after 2-days of birth paralleled with increased cardiac mass. Combined with previous studies, 327 
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our data supports that the mechanisms for these telomeric changes are likely to be due to 328 
perturbations in Tert and miR-34a expression. This miRNA could also be potentially used for 329 
therapeutic intervention for LVH before the development of end stage disease. 330 
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Figure Legends 509 
Figure 1. Telomere length of HHR and NHR. (A) Heart growth of the hypertrophic heart art (HHR) and normal heart rat (NHR) samples used 510 
in the present study. Heart size of HHR is represented as cardiac weight index (mg/g), showed as a percentage difference to NHR (normalised to 511 
100%). Body weight, heart weight and cardiac weight index values are shown in Table S1 (n=7-11 per group per age). (B) Neonatal HHR has 512 
significantly longer heart telomere compared to NHR. In 13-weeks old animals, HHR has shorter telomeres than age-matched NHR. At 38-513 
weeks of age, telomeres are once again longer in HHR than NHR. The shortening of telomeres in the HHR happened early in life († symbol) 514 
compared to NHR (# symbol), where telomere shortening occurred in late adulthood. (C) Blood telomere length was shorter in 13-weeks old 515 
HHR compared to age-matched NHR, similarly to heart telomere length. (D) Circulating telomere length is correlated to heart telomere length in 516 
13-weeks old animals. Graphs represent mean, error bars represent standard error. * indicates P<0.05, **P<0.01, ***P<0.001, †P<0.05, # 517 
#P<0.01. 518 
 519 
Figure 2. Cardiac telomerase activity in ageing HHR and NHR. (A) Neonatal HHR has significantly higher left ventricular telomerase 520 
activity compared to NHR. At 13- and 38-weeks, we did not discover significant difference in telomerase activity between strains (n=7-11 per 521 
group per age). Neonatal NHR (# symbol) and HHR († symbol) had significantly higher telomerase activity than all other ages. (B) Telomerase 522 
activity was correlated to telomere length (r=0.27, P=0.035), (C) especially in the control strain (r=0.51, P=0.005). (D) Neonatal and 38-weeks 523 
old HHR had significantly higher Tert mRNA than age-matched NHR. Neonatal NHR had significantly higher Tert mRNA than all other ages (# 524 
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symbol). 13-weeks old HHR had significantly lower Tert mRNA than other ages († symbol). (E) We did not discover significant difference in 525 
Terc RNA between HHR and NHR at any of the ages studied. 38-weeks old NHR (# symbol) and HHR († symbol) had significantly higher Terc 526 
RNA levels than other ages. Graphs represent mean, error bars represent standard error. * indicates P<0.05, **P<0.01, ***P<0.001, 527 
†††P<0.001, # #P<0.01, # # #P<0.001. 528 
 529 
Figure 3. The expression of miR-34a and its target gene Ppp1r10 in the development of left ventricular hypertrophy. (A) miR-34a was 530 
significantly over-expressed at 2-days and 13-weeks old HHR, and down-regulated at 38-weeks of age compared to age-matched NHR (n=7-11 531 
per group per age). 38-weeks old HHR († symbol) and NHR (# symbol) had significantly higher levels of miR-34a compared to other ages. (B) 532 
38-weeks old HHR had significantly higher Ppp1r10 mRNA levels than age-matched NHR. 13-weeks old HHR († symbol) had significantly 533 
lower Ppp1r10 mRNA than other ages. Neonatal NHR (# symbol) had significantly higher Ppp1r10 mRNA than other ages. Graphs represent 534 
mean, error bars represent standard error. * indicates P<0.05, **P<0.01, ***P<0.001, ††P<0.01, †††P<0.001, # #P<0.01, # # #P<0.001.  535 
 536 
 537 
 538 
539 
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Tables 540 
Table 1. Characteristics of hypertrophic heart rat (HHR) and normal heart rat (NHR) samples used in this study. 541 
Age NHR HHR 
 n Body weight (g) Heart weight (mg) CWI (mg/g) n Body weight (g) Heart weight (mg) CWI (mg/g)
2-day old 9 5.9±0.2 44.1±2.0 7.4±0.1 7 5.3±0.3 34.3±2.4** 6.4±0.2*** 
13-week old 11 205.2±15.9 697.0±44.8 3.4± 0.1 9 186.2±13.0 890.8±46.8** 4.9±0.3*** 
38-week old 9 355.0±35.7 1188.6±83.0 3.4±0.1 7 253.1±20.5* 1038.5±108.8 4.5±0.5* 
Footnote: CWI, cardiac weight index. Values are represented as mean ± standard error of mean. * indicates P<0.05, **P<0.01, ***P<0.001. 542 
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Table 2. Primers, probe assays and conditions used to validate microarray miRNA and gene expression. 543 
Official gene symbol Primer Sequence (5’3’) Annealing temperature Concentration Product length
Gapdh F: GGGGCTCTCTGCTCCTCCCTG 
R: ACGGCCAAATCCGTTCACACC 
58oC 200 nM 
200 nM 
108 bp 
Pnuts F: CTCAAGCAGAACAACACAGCG 
R: CTACTCTGGGAGCGGATGAC 
58oC 200 nM 
200 nM 
125 bp 
Tert F: AACTACGAGCGGACCAAACA 
R: CCCTGTCACATCTGCCTTAAC 
58oC 200 nM 
200 nM 
150 bp 
Terc 
 
F: TGTTATAGCTGTGGGTTCTGTTCTT 
R: CCGCTGCAGGTCTGAACTTT 
58oC 200 nM 
200 nM 
91 bp 
Official microRNA symbol TaqMan assay ID Annealing temperature   
rno-miR-34a 000426 60 oC   
4.5S 001716 60 oC   
Sno87 AF272707 60 oC   
RNU6B 001973 60 oC   
*Bp: base pairs, Fw: forward, Rv: reverse. 544 
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Table 3. Association between cardiac telomere length and molecular variables. Results are 545 
from a step-wise regression analyses used to determine the predictors of cardiac telomere 546 
length, including miR-34a, Ppp1r10, Terc, Tert, telomerase activity and strain as independent 547 
variables (F-entry probability: 0.05, removal: 0.1).  548 
Variable β±S.E. Standardised β 95% C.I. P-value 
miR-34a –0.02±0.003 –0.62 –0.03 to –0.14 <0.001 
Tert mRNA 0.015±0.007 0.22 0.001 to 0.03 0.036 
Legend: C.I., confidence interval; S.E., standard error. 549 
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